In another study, LL-37 peptide (Table 1), which is a cathelicidin-derived peptide obtained by the cleavage of the human cationic anti-microbial peptide-18 (hCAP-18) encoded by CAMP, demonstrated an effectiveness against leishmaniasis: LL-37 was able to decrease around 50% of the viability of the promastigotes of L. donovani compared to the untreated control. The gene discussed is CAMP; the disease is leishmaniasis.